• Text Size: Decrease Text SizeIncrease Text Size
  • Printer Friendly Version

Memorial Hospital Uses Antibody Infusion Treatment for COVID-19 Patients with Mild Symptoms

Posted Date: December 9, 2020

Memorial Hospital is now providing monoclonal antibody infusion treatments for patients diagnosed with COVID-19 that are not requiring hospital admission. Monoclonal antibody therapy is given to patients to reduce the risk of progression of disease and to reduce hospitalizations in those diagnosed with COVID-19. The treatment is specifically for patients with mild to moderate symptoms and is being supplied per the Food and Drug Administrations (FDA) Emergency Use Authorization. Memorial Hospital has received a limited supply of two monoclonal antibody medications: Bamlanivimab and Regeneron. To date, approximately 50 patients have been infused.

Patients who meet criteria will be given the treatment at Memorial Hospital at Gulfport. Patients should expect a minimum of two hours to receive their therapy. There are specific requirements that must be met including:

  • Positive COVID-19 result
  • Age 18 years or older with specific risk factors
  • Signs and symptoms less than 10 days
  • Mild to moderate symptoms
  • No recent hospitalizations related to COVID-19
  • No new supplemental oxygen therapy initiated or an increase need for prior oxygen use.


For patients who are interested in receiving monoclonal antibody treatment, please contact your Primary Care Provider (PCP) or call 228-867-5000 to be connected with the team for screening and coordination. Please note that quantities are limited. Memorial Hospital remains committed to improving the healthcare needs of our community.